1/33
Looks like no tags are added yet.
Hyperkalemia — ECG Changes
Produces peaked T waves (best seen in precordial leads like V2), a shortened QT interval, and small or indiscernible P waves (seen in leads V5–V6); severe levels (> 6.5 mEq/L) can progress to ventricular fibrillation
Calcium Chloride / Calcium Gluconate in Hyperkalemic ECG Changes
Used in severe hyperkalemia (> 6.5 mEq/L) to stabilize the cardiac resting membrane potential and prevent ventricular fibrillation; does not lower serum potassium levels
Hypokalemia — Cardiac & ECG Considerations
Causes cardiac arrhythmias and ECG abnormalities requiring continuous cardiac monitoring during IV potassium replacement when serum K+ < 3.0 mEq/L or marked symptoms are present. (Classic ECG findings: flattened or inverted T waves, ST-segment depression, and prominent U waves.)
Hypocalcemia & Hypercalcemia — Classic ECG Changes
(Supplement to lecture notes) Hypocalcemia prolongs the QT interval (via prolonged ST segment), whereas hypercalcemia shortens the QT interval
Normal Serum Calcium & Hormonal Regulation
Reference range is 2.1–2.6 mmol/L; regulated by PTH (raises serum Ca2+ via bone resorption, renal reabsorption, and vitamin D activation while increasing urinary phosphate excretion), calcitriol (increases GI absorption of Ca2+ and phosphate), and calcitonin (lowers serum Ca2+ by inhibiting bone resorption)
Calcium Gluconate 10% Injection (Acute Hypocalcemia)
Administered via slow IV infusion to rapidly correct acute symptomatic hypocalcemia; warm vial if crystallization occurs and discard unused portion
Calcitriol (Rocaltrol®)
Most active form of vitamin D 3, 100 times more potent than vitamin D3; treats chronic hypocalcemia by directly stimulating intestinal Ca2 absorption without requiring renal 1alpha-hydroxylase activation
Paricalcitol (Zemplar®)
Synthetic vitamin D2 analog used in chronic hypocalcemia and CKD mineral bone disorder to increase calcium absorption and suppress PTH
Ergocalciferol & Cholecalciferol
Oral vitamin D2</strong></span>(ergocalciferol)and<strong>vitamin</strong><span><strong>D3 (cholecalciferol) supplements used alongside oral calcium (and magnesium if deficient) to manage chronic hypocalcemia
Hypercalcemia Treatment Thresholds
Asymptomatic levels < 12\ require no treatment; moderate levels (12–14mg/dL} require hydration if asymptomatic or targeted therapy if symptomatic; levels > 14\require aggressive treatment regardless of symptoms
Hypercalcemic Crisis Regimen
First-line acute management consists of 0.9% normal saline rehydration followed by furosemide (Lasix®) loop diuresis (promotes urinary Ca^2+ excretion), calcitonin (rapidly inhibits bone resorption), and bisphosphonates
Bisphosphonates (Hypercalcemia)
Accumulate in bone and powerfully inhibit osteoclast-mediated bone resorption; key for malignancy-associated or severe hypercalcemia.
Cinacalcet (Sensipar®)
Oral calcimimetic that binds the 7-transmembrane domain of the calcium-sensing receptor (CaSR) to increase receptor sensitivity and suppress PTH secretion; approved for secondary hyperparathyroidism (HPT) in CKD on dialysis, parathyroid carcinoma, and tertiary HPT; acts as a strong CYP2D6 inhibitor and CYP3A4 substrate.
Etelcalcetide (Parsabiv®)
IV synthetic peptide calcimimetic that allosterically activates the extracellular domain of the CaSR to lower PTH in adult CKD patients with secondary HPT on hemodialysis; adverse effects include hypocalcemia, muscle spasms, GI upset, headache, and paresthesias (numbness/tingling in extremities or perioral area)
Hemodialysis / Peritoneal Dialysis (Hypercalcemia)
Reserved for severe, refractory hypercalcemia, particularly in patients with concurrent renal failure
Normal Serum Phosphorus & Severity Thresholds
Reference range is 2.5–4.5mg/dL; moderate hypophosphatemia is 1.0–2.4mg/dL and severe hypophosphatemia is < 1.0mg/dL
Oral Phosphate Replacements (Hypophosphatemia)
Preferred first-line therapy (limited by diarrhea; use caution in CKD
IV Phosphate Replacements (Severe Hypophosphatemia)
Sodium Phosphate IV (93 mg P and 4.0 mEq Na/mL) and Potassium Phosphate IV (93mgP and 4.4mEqK/mL for severe depletion (< 1.0\ mg/dL or when oral intake is not possible.
Phosphate Binders — Mechanism of Action (Hyperphosphatemia
Bind dietary phosphate in the GI lumen to form insoluble complexes excreted in the feces, preventing intestinal absorption in advanced CKD.
uminum Hydroxide (Phosphate Binder)
Calcium-free liquid binder; effective and low cost, but limited to 4 weeks of use due to risks of osteomalacia, anemia, and CNS toxicity.
Calcium Acetate (PhosLo®) & Calcium Carbonate (Phosphate Binders):
ow-cost, effective binders containing 169 mg (PhosLo® $667 mg) and 400 mg (calcium carbonate 1 g) elemental calcium; limited by high pill burden and risks of hypercalcemia, vascular calcification, and adynamic bone disease (ADB).
Sevelamer Carbonate (Renvela®)
Calcium-free polymeric phosphate binder (800 mg); also lowers LDL cholesterol, but carries a high pill burden, swallowing difficulties, and interferes with fat-soluble vitamin D and K absorption.
Lanthanum Carbonate (Fosrenol®)
Calcium-free phosphate binder (750 mg) with a low pill burden; primary adverse effects are gastrointestinal.
Sucroferric Oxyhydroxide (Velphoro®)
Calcium-free, iron-based phosphate binder (500 mg) with a low pill burden and potential to increase transferrin, iron, and hemoglobin; drawbacks include high cost and potential long-term iron accumulation.
Tenapanor (Alternative Hyperphosphatemia Agent)
Small-molecule inhibitor of intestinal NHE3 (Na+/H exchanger isoform 3) that reduces passive paracellular phosphate absorption.
Nicotinamide & ASP3325 (Alternative Hyperphosphatemia Agents)
Inhibit active sodium-dependent transcellular NaPi-IIb cotransporters in the enterocyte to reduce intestinal phosphate uptake.
Pathophysiology of Anemia in CKD
Renal injury causes erythropoietin-producing peritubular interstitial cells (EPCs) to transdifferentiate into collagen-producing myofibroblasts, decreasing endogenous EPO production; concurrent iron deficiency (25–70% prevalence) further impairs hemoglobin synthesis.
Oral Iron Supplements (CKD Anemia):
nclude ferrous sulfate 325 mg tab = 65mg elemental iron), ferrous gluconate (Fergon®) (324 mg tab = 37.5 mg elemental iron), and ferric citrate (Auryxia®) (also functions as a phosphate binder).
ntravenous (IV) Iron Supplements (CKD Anemia)
referred in hemodialysis or patients intolerant/unresponsive to oral iron; includes iron sucrose (Venofer®) (100 mg/5 mL), ferumoxytol (Feraheme®) (510 mg/17 mL), ferric carboxymaltose (Injectafer®), iron dextran (Infed®), and ferric gluconate.
Erythropoietin-Stimulating Agents (ESAs) — Mechanism
Recombinant human EPO analogs that bind EPO receptors (EPOR) on bone marrow erythroid progenitors (CFU-E, proerythroblasts, basophilic erythroblasts) to stimulate red blood cell proliferation and raise hemoglobin.
Epoetin Alfa (Epogen®, Procrit®, Eprex®; Biosimilar: Retacrit™)
First-generation recombinant human EPO used in CKD and chemotherapy-induced anemia; shorter half-life requiring 3-times-weekly administration
Darbepoetin Alfa (Aranesp®) & Methoxy PEG-Epoetin Beta (Mircera®)
Second-generation (darbepoetin alfa) and third-generation pegylated (Mircera®) ESAs engineered with longer half-lives for less frequent dosing than epoetin alfa.
Daprodustat (Jesduvroq®) — Mechanism & Indication:
Oral hypoxia-inducible factor prolyl hydroxylase (HIF-PHD) inhibitor; prevents PHD-mediated hydroxylation and VHL proteasomal degradation of HIF-alpha, increasing nuclear HIF transcription of endogenous EPO and erythropoiesis; approved for CKD anemia in adults on dialysis for > 4 months (not approved for non-dialysis patients)
Daprodustat (Jesduvroq®) — Administration & Adverse Effects
Swallow tablets whole (do not cut, crush, or chew); noninferior to darbepoetin alfa for hemoglobin maintenance and cardiovascular safety; adverse effects include hypertension, thrombotic vascular events, abdominal pain, dizziness, and allergic reactions.